WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

During an AHA press conference, Li explained that each component of the triple-receptor agonist compensates for side effects ...

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...